1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Mmunomedics Technology 1.2.3 Immunogen Technology 1.2.4 Seattle Genetics Technology 1.2.5 Others 1.3 Market by Application 1.3.1 Global Antibody Drug Conjugate Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Lymphoma 1.3.3 Leukemia 1.3.4 Multiple Myeloma 1.3.5 Skin Cancer 1.3.6 Colon Cancer 1.3.7 Glioblastoma 1.3.8 Pancreatic Cancer 1.3.9 Prostate Cancer 1.3.10 Solid Tumor 1.3.11 Breast Cancer 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Antibody Drug Conjugate Therapeutics Market Perspective (2017-2028) 2.2 Antibody Drug Conjugate Therapeutics Growth Trends by Region 2.2.1 Antibody Drug Conjugate Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Antibody Drug Conjugate Therapeutics Historic Market Size by Region (2017-2022) 2.2.3 Antibody Drug Conjugate Therapeutics Forecasted Market Size by Region (2023-2028) 2.3 Antibody Drug Conjugate Therapeutics Market Dynamics 2.3.1 Antibody Drug Conjugate Therapeutics Industry Trends 2.3.2 Antibody Drug Conjugate Therapeutics Market Drivers 2.3.3 Antibody Drug Conjugate Therapeutics Market Challenges 2.3.4 Antibody Drug Conjugate Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue 3.1.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue (2017-2022) 3.1.2 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Players (2017-2022) 3.2 Global Antibody Drug Conjugate Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Antibody Drug Conjugate Therapeutics Revenue 3.4 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio 3.4.1 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Therapeutics Revenue in 2021 3.5 Antibody Drug Conjugate Therapeutics Key Players Head office and Area Served 3.6 Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service 3.7 Date of Enter into Antibody Drug Conjugate Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Antibody Drug Conjugate Therapeutics Breakdown Data by Type 4.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Type (2017-2022) 4.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2023-2028) 5 Antibody Drug Conjugate Therapeutics Breakdown Data by Application 5.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Application (2017-2022) 5.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Antibody Drug Conjugate Therapeutics Market Size (2017-2028) 6.2 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) 6.3 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Antibody Drug Conjugate Therapeutics Market Size (2017-2028) 7.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) 7.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size (2017-2028) 8.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) 8.3 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Antibody Drug Conjugate Therapeutics Market Size (2017-2028) 9.2 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) 9.3 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size (2017-2028) 10.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) 10.3 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Bayer AG 11.1.1 Bayer AG Company Detail 11.1.2 Bayer AG Business Overview 11.1.3 Bayer AG Antibody Drug Conjugate Therapeutics Introduction 11.1.4 Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.1.5 Bayer AG Recent Development 11.2 Pfizer 11.2.1 Pfizer Company Detail 11.2.2 Pfizer Business Overview 11.2.3 Pfizer Antibody Drug Conjugate Therapeutics Introduction 11.2.4 Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.2.5 Pfizer Recent Development 11.3 Hoffman-Le Roche 11.3.1 Hoffman-Le Roche Company Detail 11.3.2 Hoffman-Le Roche Business Overview 11.3.3 Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Introduction 11.3.4 Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.3.5 Hoffman-Le Roche Recent Development 11.4 Seattle Genetics 11.4.1 Seattle Genetics Company Detail 11.4.2 Seattle Genetics Business Overview 11.4.3 Seattle Genetics Antibody Drug Conjugate Therapeutics Introduction 11.4.4 Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.4.5 Seattle Genetics Recent Development 11.5 ImmunoGen 11.5.1 ImmunoGen Company Detail 11.5.2 ImmunoGen Business Overview 11.5.3 ImmunoGen Antibody Drug Conjugate Therapeutics Introduction 11.5.4 ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.5.5 ImmunoGen Recent Development 11.6 Genentech 11.6.1 Genentech Company Detail 11.6.2 Genentech Business Overview 11.6.3 Genentech Antibody Drug Conjugate Therapeutics Introduction 11.6.4 Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.6.5 Genentech Recent Development 11.7 Synthon Holding 11.7.1 Synthon Holding Company Detail 11.7.2 Synthon Holding Business Overview 11.7.3 Synthon Holding Antibody Drug Conjugate Therapeutics Introduction 11.7.4 Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.7.5 Synthon Holding Recent Development 11.8 Sanofi 11.8.1 Sanofi Company Detail 11.8.2 Sanofi Business Overview 11.8.3 Sanofi Antibody Drug Conjugate Therapeutics Introduction 11.8.4 Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.8.5 Sanofi Recent Development 11.9 Genmab 11.9.1 Genmab Company Detail 11.9.2 Genmab Business Overview 11.9.3 Genmab Antibody Drug Conjugate Therapeutics Introduction 11.9.4 Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.9.5 Genmab Recent Development 11.10 Amgen 11.10.1 Amgen Company Detail 11.10.2 Amgen Business Overview 11.10.3 Amgen Antibody Drug Conjugate Therapeutics Introduction 11.10.4 Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.10.5 Amgen Recent Development 11.11 Novartis 11.11.1 Novartis Company Detail 11.11.2 Novartis Business Overview 11.11.3 Novartis Antibody Drug Conjugate Therapeutics Introduction 11.11.4 Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.11.5 Novartis Recent Development 11.12 Eli Lilly 11.12.1 Eli Lilly Company Detail 11.12.2 Eli Lilly Business Overview 11.12.3 Eli Lilly Antibody Drug Conjugate Therapeutics Introduction 11.12.4 Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) 11.12.5 Eli Lilly Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Mmunomedics Technology Table 3. Key Players of Immunogen Technology Table 4. Key Players of Seattle Genetics Technology Table 5. Key Players of Others Table 6. Global Antibody Drug Conjugate Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Antibody Drug Conjugate Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Antibody Drug Conjugate Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Antibody Drug Conjugate Therapeutics Market Share by Region (2017-2022) Table 10. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Antibody Drug Conjugate Therapeutics Market Share by Region (2023-2028) Table 12. Antibody Drug Conjugate Therapeutics Market Trends Table 13. Antibody Drug Conjugate Therapeutics Market Drivers Table 14. Antibody Drug Conjugate Therapeutics Market Challenges Table 15. Antibody Drug Conjugate Therapeutics Market Restraints Table 16. Global Antibody Drug Conjugate Therapeutics Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Antibody Drug Conjugate Therapeutics Market Share by Players (2017-2022) Table 18. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2021) Table 19. Ranking of Global Top Antibody Drug Conjugate Therapeutics Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Antibody Drug Conjugate Therapeutics Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service Table 23. Date of Enter into Antibody Drug Conjugate Therapeutics Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Antibody Drug Conjugate Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2017-2022) Table 27. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2023-2028) Table 29. Global Antibody Drug Conjugate Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2017-2022) Table 31. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2023-2028) Table 33. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 34. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 35. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 36. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 37. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 38. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2023-2028) & (US$ Million) Table 39. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 40. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 41. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 42. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 43. Bayer AG Company Detail Table 44. Bayer AG Business Overview Table 45. Bayer AG Antibody Drug Conjugate Therapeutics Product Table 46. Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 47. Bayer AG Recent Development Table 48. Pfizer Company Detail Table 49. Pfizer Business Overview Table 50. Pfizer Antibody Drug Conjugate Therapeutics Product Table 51. Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 52. Pfizer Recent Development Table 53. Hoffman-Le Roche Company Detail Table 54. Hoffman-Le Roche Business Overview Table 55. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Product Table 56. Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 57. Hoffman-Le Roche Recent Development Table 58. Seattle Genetics Company Detail Table 59. Seattle Genetics Business Overview Table 60. Seattle Genetics Antibody Drug Conjugate Therapeutics Product Table 61. Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 62. Seattle Genetics Recent Development Table 63. ImmunoGen Company Detail Table 64. ImmunoGen Business Overview Table 65. ImmunoGen Antibody Drug Conjugate Therapeutics Product Table 66. ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 67. ImmunoGen Recent Development Table 68. Genentech Company Detail Table 69. Genentech Business Overview Table 70. Genentech Antibody Drug Conjugate Therapeutics Product Table 71. Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 72. Genentech Recent Development Table 73. Synthon Holding Company Detail Table 74. Synthon Holding Business Overview Table 75. Synthon Holding Antibody Drug Conjugate Therapeutics Product Table 76. Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 77. Synthon Holding Recent Development Table 78. Sanofi Company Detail Table 79. Sanofi Business Overview Table 80. Sanofi Antibody Drug Conjugate Therapeutics Product Table 81. Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 82. Sanofi Recent Development Table 83. Genmab Company Detail Table 84. Genmab Business Overview Table 85. Genmab Antibody Drug Conjugate Therapeutics Product Table 86. Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 87. Genmab Recent Development Table 88. Amgen Company Detail Table 89. Amgen Business Overview Table 90. Amgen Antibody Drug Conjugate Therapeutics Product Table 91. Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 92. Amgen Recent Development Table 93. Novartis Company Detail Table 94. Novartis Business Overview Table 95. Novartis Antibody Drug Conjugate TherapeuticsProduct Table 96. Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 97. Novartis Recent Development Table 98. Eli Lilly Company Detail Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Antibody Drug Conjugate TherapeuticsProduct Table 101. Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million) Table 102. Eli Lilly Recent Development Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Antibody Drug Conjugate Therapeutics Market Share by Type: 2021 VS 2028 Figure 2. Mmunomedics Technology Features Figure 3. Immunogen Technology Features Figure 4. Seattle Genetics Technology Features Figure 5. Others Features Figure 6. Global Antibody Drug Conjugate Therapeutics Market Share by Application in 2021 & 2028 Figure 7. Lymphoma Case Studies Figure 8. Leukemia Case Studies Figure 9. Multiple Myeloma Case Studies Figure 10. Skin Cancer Case Studies Figure 11. Colon Cancer Case Studies Figure 12. Glioblastoma Case Studies Figure 13. Pancreatic Cancer Case Studies Figure 14. Prostate Cancer Case Studies Figure 15. Solid Tumor Case Studies Figure 16. Breast Cancer Case Studies Figure 17. Antibody Drug Conjugate Therapeutics Report Years Considered Figure 18. Global Antibody Drug Conjugate Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 19. Global Antibody Drug Conjugate Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 20. Global Antibody Drug Conjugate Therapeutics Market Share by Region: 2021 VS 2028 Figure 21. Global Antibody Drug Conjugate Therapeutics Market Share by Players in 2021 Figure 22. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2021) Figure 23. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate Therapeutics Revenue in 2021 Figure 24. North America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. North America Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028) Figure 26. United States Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Canada Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Europe Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Europe Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028) Figure 30. Germany Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. France Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. U.K. Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Italy Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Russia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Nordic Countries Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Share by Region (2017-2028) Figure 38. China Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Japan Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. South Korea Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Southeast Asia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. India Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Australia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Latin America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Latin America Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028) Figure 46. Mexico Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Brazil Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 49. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028) Figure 50. Turkey Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 51. Saudi Arabia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 52. Bayer AG Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 53. Pfizer Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 54. Hoffman-Le Roche Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 55. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 56. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 57. Genentech Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 58. Synthon Holding Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 59. Sanofi Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 60. Genmab Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 61. Amgen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 62. Novartis Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 63. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022) Figure 64. Bottom-up and Top-down Approaches for This Report Figure 65. Data Triangulation Figure 66. Key Executives Interviewed

Bayer AG Pfizer Hoffman-Le Roche Seattle Genetics ImmunoGen Genentech Synthon Holding Sanofi Genmab Amgen Novartis Eli Lilly